{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:34:33Z","timestamp":1774420473009,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This study was supported by an SRA grant from AstraZeneca and philanthropic funds from the Kimmel Research fund and various donor funds"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bruton\u2019s tyrosine kinase inhibitors (BTKi) and CAR T-cell therapy have demonstrated tremendous clinical benefits in mantle cell lymphoma (MCL) patients, but intrinsic or acquired resistance inevitably develops. In this study, we assessed the efficacy of the highly potent and selective MCL-1 inhibitor AZD5991 in various therapy-resistant MCL cell models. AZD5991 markedly induced apoptosis in these cells. In addition to liberating BAK from the antiapoptotic MCL-1\/BAK complex for the subsequent apoptosis cascade, AZD5991 downregulated inhibitor of apoptosis proteins (IAPs) through a BAK-dependent mechanism to amplify the apoptotic signal. The combination of AZD5991 with venetoclax enhanced apoptosis and reduced mitochondrial oxygen consumption capacity in MCL cell lines irrespective of their BTKi or venetoclax sensitivity. This combination also dramatically inhibited tumor growth and prolonged mouse survival in two aggressive MCL patient-derived xenograft models. Mechanistically, the augmented cell lethality was accompanied by the synergistic suppression of IAPs. Supporting this notion, the IAP antagonist BV6 induced dramatic apoptosis in resistant MCL cells and sensitized the resistant MCL cells to venetoclax. Our study uncovered another unique route for MCL-1 inhibitor to trigger apoptosis, implying that the pro-apoptotic combination of IAP antagonists and apoptosis inducers could be further exploited for MCL patients with multiple therapeutic resistance.<\/jats:p>","DOI":"10.1038\/s41419-023-06233-w","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T06:01:55Z","timestamp":1698904915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins"],"prefix":"10.1038","volume":"14","author":[{"given":"Yijing","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng-Huan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian Changying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxuan","family":"Che","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jovanny","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianci","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6231-5225","authenticated-orcid":false,"given":"Fangfang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret Elizabeth","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8439-6043","authenticated-orcid":false,"given":"Yixin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preetesh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1910-8076","authenticated-orcid":false,"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"6233_CR1","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ajh.25487","volume":"94","author":"P Jain","year":"2019","unstructured":"Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol. 2019;94:710\u201325.","journal-title":"Am J Hematol"},{"key":"6233_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14920","volume":"8","author":"X Zhao","year":"2017","unstructured":"Zhao X, Lwin T, Silva A, Shah B, Tao J, Fang B, et al. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017;8:14920.","journal-title":"Nat Commun"},{"key":"6233_CR3","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl J Med. 2020;382:1331\u201342.","journal-title":"N. Engl J Med"},{"key":"6233_CR4","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13045-021-01143-w","volume":"14","author":"VC Jiang","year":"2021","unstructured":"Jiang VC, Liu Y, Jordan A, McIntosh J, Li Y, Che Y, et al. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma. J Hematol Oncol. 2021;14:132.","journal-title":"J Hematol Oncol"},{"key":"6233_CR5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.bcp.2019.01.015","volume":"162","author":"T Knight","year":"2019","unstructured":"Knight T, Luedtke D, Edwards H, Taub JW, Ge Y. A delicate balance - The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics. Biochem Pharm. 2019;162:250\u201361.","journal-title":"Biochem Pharm"},{"key":"6233_CR6","first-page":"2547","volume":"6","author":"U Zangemeister-Wittke","year":"2000","unstructured":"Zangemeister-Wittke U, Leech SH, Olie RA, Sim\u00f5es-W\u00fcst AP, Gautschi O, Luedke GH, et al. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res. 2000;6:2547\u201355.","journal-title":"Clin Cancer Res"},{"key":"6233_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00402-2","volume":"11","author":"MY Wang","year":"2021","unstructured":"Wang MY, Li T, Ren Y, Shah BD, Lwin T, Gao J, et al. MCL-1 dependency as a novel vulnerability for aggressive B cell lymphomas. Blood Cancer J. 2021;11:14.","journal-title":"Blood Cancer J"},{"key":"6233_CR8","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J Clin Oncol. 2017;35:826\u201333.","journal-title":"J Clin Oncol"},{"key":"6233_CR9","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","volume":"104","author":"TA Eyre","year":"2019","unstructured":"Eyre TA, Walter HS, Iyengar S, Follows G, Cross M, Fox CP, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019;104:e68\u2013e71.","journal-title":"Haematologica"},{"key":"6233_CR10","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1080\/10428194.2017.1283032","volume":"58","author":"P Bose","year":"2017","unstructured":"Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma. 2017;58:2026\u201339.","journal-title":"Leuk Lymphoma"},{"key":"6233_CR11","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1158\/1078-0432.CCR-17-3004","volume":"24","author":"LV Pham","year":"2018","unstructured":"Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, et al. Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas. Clin Cancer Res. 2018;24:3967.","journal-title":"Clin Cancer Res"},{"key":"6233_CR12","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.1182\/blood.V97.12.3902","volume":"97","author":"P Zhou","year":"2001","unstructured":"Zhou P, Levy NB, Xie H, Qian L, Lee CY, Gascoyne RD, et al. MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. Blood. 2001;97:3902\u20139.","journal-title":"Blood"},{"key":"6233_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1101\/gad.232009.113","volume":"28","author":"GL Kelly","year":"2014","unstructured":"Kelly GL, Grabow S, Glaser SP, Fitzsimmons L, Aubrey BJ, Okamoto T, et al. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev. 2014;28:58\u201370.","journal-title":"Genes Dev"},{"key":"6233_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nrd3627","volume":"11","author":"S Fulda","year":"2012","unstructured":"Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov. 2012;11:109\u201324.","journal-title":"Nat Rev Drug Discov"},{"key":"6233_CR15","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1586\/14737140.7.9.1255","volume":"7","author":"S Fulda","year":"2007","unstructured":"Fulda S. Inhibitor of apoptosis proteins as targets for anticancer therapy. Expert Rev Anticancer Ther. 2007;7:1255\u201364.","journal-title":"Expert Rev Anticancer Ther"},{"key":"6233_CR16","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s10495-017-1375-1","volume":"22","author":"R Rathore","year":"2017","unstructured":"Rathore R, McCallum JE, Varghese E, Florea AM, Busselberg D. Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs). Apoptosis. 2017;22:898\u2013919.","journal-title":"Apoptosis"},{"key":"6233_CR17","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/ajh.20656","volume":"81","author":"Y Nakagawa","year":"2006","unstructured":"Nakagawa Y, Abe S, Kurata M, Hasegawa M, Yamamoto K, Inoue M, et al. IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol. 2006;81:824\u201331.","journal-title":"Am J Hematol"},{"key":"6233_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1158\/1535-7163.MCT-18-0478","volume":"18","author":"CJ Li","year":"2019","unstructured":"Li CJ, Jiang C, Liu Y, Bell T, Ma W, Ye Y, et al. Pleiotropic action of novel Bruton\u2019s Tyrosine Kinase Inhibitor BGB-3111 in mantle cell lymphoma. Mol Cancer Ther. 2019;18:267\u201377.","journal-title":"Mol Cancer Ther"},{"key":"6233_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22872-z","volume":"12","author":"S Zhang","year":"2021","unstructured":"Zhang S, Jiang VC, Han G, Hao D, Lian J, Liu Y, et al. Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nat Commun. 2021;12:2877.","journal-title":"Nat Commun"},{"key":"6233_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01655-0","volume":"21","author":"VC Jiang","year":"2022","unstructured":"Jiang VC, Hao D, Jain P, Li Y, Cai Q, Yao Y, et al. TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma. Mol Cancer. 2022;21:185.","journal-title":"Mol Cancer"},{"key":"6233_CR21","doi-asserted-by":"publisher","first-page":"eaau1167","DOI":"10.1126\/scitranslmed.aau1167","volume":"11","author":"L Zhang","year":"2019","unstructured":"Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med. 2019;11:eaau1167.","journal-title":"Sci Transl Med"},{"key":"6233_CR22","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-21-0464","volume":"27","author":"T Liu","year":"2021","unstructured":"Liu T, Lam V, Thieme E, Sun D, Wang X, Xu F, et al. Pharmacologic targeting of Mcl-1 induces mitochondrial dysfunction and apoptosis in B-Cell lymphoma cells in a TP53- and BAX-dependent manner. Clin Cancer Res. 2021;27:4910\u201322.","journal-title":"Clin Cancer Res"},{"key":"6233_CR23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","volume":"36","author":"R Gui\u00e8ze","year":"2019","unstructured":"Gui\u00e8ze R, Liu VM, Rosebrock D, Jourdain AA, Hern\u00e1ndez-S\u00e1nchez M, Martinez Zurita A, et al. Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies. Cancer Cell. 2019;36:369\u201384.e13.","journal-title":"Cancer Cell"},{"key":"6233_CR24","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1038\/s41375-019-0421-0","volume":"33","author":"KT Siu","year":"2019","unstructured":"Siu KT, Huang C, Panaroni C, Mukaihara K, Fulzele K, Soucy R, et al. BCL2 blockade overcomes MCL1 resistance in multiple myeloma. Leukemia. 2019;33:2098\u2013102.","journal-title":"Leukemia"},{"key":"6233_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07551-w","volume":"9","author":"AE Tron","year":"2018","unstructured":"Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018;9:5341.","journal-title":"Nat Commun"},{"key":"6233_CR26","doi-asserted-by":"publisher","first-page":"100672","DOI":"10.1016\/j.blre.2020.100672","volume":"44","author":"AH Wei","year":"2020","unstructured":"Wei AH, Roberts AW, Spencer A, Rosenberg AS, Siegel D, Walter RB, et al. Targeting MCL-1 in hematologic malignancies: rationale and progress. Blood Rev. 2020;44:100672.","journal-title":"Blood Rev"},{"key":"6233_CR27","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1182\/bloodadvances.2018016048","volume":"2","author":"J Lee","year":"2018","unstructured":"Lee J, Zhang LL, Wu W, Guo H, Li Y, Sukhanova M, et al. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma. Blood Adv. 2018;2:2039\u201351.","journal-title":"Blood Adv"},{"key":"6233_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3324\/haematol.2020.260331","volume":"107","author":"BZ Carter","year":"2020","unstructured":"Carter BZ, Mak PY, Tao W, Warmoes M, Lorenzi PL, Mak D, et al. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition. Haematologica. 2020;107:58\u201376.","journal-title":"Haematologica"},{"key":"6233_CR29","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/ncb2488","volume":"14","author":"RM Perciavalle","year":"2012","unstructured":"Perciavalle RM, Stewart DP, Koss B, Lynch J, Milasta S, Bathina M, et al. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol. 2012;14:575\u201383.","journal-title":"Nat Cell Biol"},{"key":"6233_CR30","doi-asserted-by":"publisher","first-page":"101015","DOI":"10.1016\/j.isci.2020.101015","volume":"23","author":"ML Rasmussen","year":"2020","unstructured":"Rasmussen ML, Taneja N, Neininger AC, Wang L, Robertson GL, Riffle SN, et al. MCL-1 inhibition by selective BH3 mimetics disrupts mitochondrial dynamics causing loss of viability and functionality of human cardiomyocytes. iScience. 2020;23:101015.","journal-title":"iScience"},{"key":"6233_CR31","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.cmet.2017.09.009","volume":"26","author":"KM Lee","year":"2017","unstructured":"Lee KM, Giltnane JM, Balko JM, Schwarz LJ, Guerrero-Zotano AL, Hutchinson KE, et al. MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation. Cell Metab. 2017;26:633\u201347.e7.","journal-title":"Cell Metab"},{"key":"6233_CR32","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3390\/cancers14071671","volume":"14","author":"P Cetraro","year":"2022","unstructured":"Cetraro P, Plaza-Diaz J, MacKenzie A, Abadia-Molina F. A review of the current impact of inhibitors of apoptosis proteins and their repression in cancer. Cancers (Basel). 2022;14:1671.","journal-title":"Cancers (Basel)"},{"key":"6233_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fped.2014.00075","volume":"2","author":"E Rettinger","year":"2014","unstructured":"Rettinger E, Glatthaar A, Abhari BA, Oelsner S, Pfirrmann V, Huenecke S, et al. SMAC mimetic BV6 enables sensitization of resistant tumor cells but also affects cytokine-induced killer (CIK) cells: a potential challenge for combination therapy. Front Pediatr. 2014;2:75.","journal-title":"Front Pediatr"},{"key":"6233_CR34","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.4103\/jcrt.JCRT_1281_20","volume":"18","author":"I Ahmad","year":"2022","unstructured":"Ahmad I, Dera AA, Irfan S, Rajagopalan P, Ali Beg MM, Alshahrani MY, et al. BV6 enhances apoptosis in Lung cancer cells by ameliorating caspase expressions through attenuation of XIAP, cIAP-1, and cIAP-2 proteins. J Cancer Res Ther. 2022;18:1651\u20137.","journal-title":"J Cancer Res Ther"},{"key":"6233_CR35","doi-asserted-by":"publisher","first-page":"5750","DOI":"10.1021\/acs.jmedchem.8b01668","volume":"62","author":"H Cong","year":"2019","unstructured":"Cong H, Xu L, Wu Y, Qu Z, Bian T, Zhang W, et al. Inhibitor of apoptosis protein (IAP) antagonists in anticancer agent discovery: current status and perspectives. J Med Chem. 2019;62:5750\u201372.","journal-title":"J Med Chem"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06233-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06233-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06233-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T06:02:00Z","timestamp":1698904920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06233-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":35,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["6233"],"URL":"https:\/\/doi.org\/10.1038\/s41419-023-06233-w","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]},"assertion":[{"value":"16 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MW is consultant to AbbVie, Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Deciphera, InnoCare, Janssen, Kite Pharma, Leukemia & Lymphoma Society, Lilly, Merck, Milken Institute, Oncternal, Parexel, Pepromene Bio, Pharmacyclics, and VelosBio, and he has received research support from Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Celgene, Genmab, Genentech, Innocare, Janssen, Juno Therapeutics, Kite Pharma, Lilly, Loxo Oncology, Molecular Templates, Oncternal, Pharmacyclics, VelosBio, Vincerx. M.W. also received a speaker honorarium from AbbVie, Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Dava Oncology, Eastern Virginia Medical School, IDEOlogy Health, Janssen, Kite Pharma, Leukemia & Lymphoma Society, LLC TS Oncology, Medscape, Meeting Minds Experts, MJH Life Sciences, Merck, Moffit Cancer Center, Oncology Specialty Group, OncLive, Pharmacyclics, Physicians Education Resources (PER), Practice Point Communications (PPC), and Studio ER Congressi. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Cell samples were acquired from patients and healthy donors after obtaining written informed consent following the University of Texas MD Anderson Cancer Center Institutional Review Board-approved protocols and in accordance with the Declaration of Helsinki. The Institutional Animal Care and Use Committee of The University of Texas MD Anderson Cancer Center approved the experimental protocols involving animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors have read and approved the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"714"}}